-

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Rentokil Initial plc (RTO) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Rentokil Initial plc (“Rentokil” or the “Company”) (NYSE: RTO) investors concerning the Company’s possible violations of federal securities laws.

On April 18, 2024, Rentokil released its first quarter 2024 financial results, disclosing that organic revenue growth in North America increased by only 1.5% year-over-year, below prior guidance of 2% for the first quarter. On this news, Rentokil’s stock price fell $2.64, or 9.3%, to close at $25.61 per share on April 18, 2024, thereby injuring investors.

Then, on September 11, 2024, Rentokil issued an unscheduled “Trading Update,” disclosing that it now expected only 1% North America organic revenue growth for the second half of 2024, explaining that “the trading performance in July and August was lower than anticipated,” and that “there has also been some modest disruption to organic growth from branch integration.” The Company further stated that the issues were “a manifestation of execution challenges.”

On this news, Rentokil’s stock price fell $6.65, or 21%, to close at $24.95 per share on September 11, 2024, thereby injuring investors further.

If you purchased Rentokil securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847 or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NYSE:RTO

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether the Company may have violated the federal securities laws. The investigation comes after a August 10, 2026 disclosure concerning Tenax Therapeutics, Inc....

Did You Lose Money on Everest Group, Ltd. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 11.4% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Everest Group, Ltd. ("Everest" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Everest Group, Ltd. (NYSE: EG) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 27, 2025 disclosure concerning Everest Group, Ltd.Investors with los...

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Merck & Co., Inc. (NYSE: MRK) investors into whether the Company may have violated the federal securities laws. The investigation comes after an October 22, 2026 disclosure concerning Merck & Co., Inc. Investors...
Back to Newsroom